{"a": [["A study to determine the efficacy and safety of albiglutide as compared with liraglutide.", "2011"], ["Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes", "2011"], ["The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes", "2011"], ["Efficacy assessment of insulin glargine versus liraglutide after oral agent failure (EAGLE)", "2011"], ["Comparison of two treatment regimens (sitagliptin versus liraglutide) on participants who failed to achieve good glucose control on metformin alone (MK\u20100431\u2010403)", "2011"], ["Dual action of liraglutide and insulin degludec in type 2 diabetes: a trial comparing the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in subjects with type 2 diabetes (DUAL\u2122 I)", "2011"], ["GLP\u20101 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL\u2010X)", "2011"], ["GLP\u20101 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL\u2010S)", "2011"], ["GLP\u20101 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL\u2010P)", "2011"], ["24\u2010week treatment with lixisenatide in type 2 diabetes insufficiently controlled with metformin and insulin glargine", "2011"], ["24\u2010week study comparing lixisenatide to sitagliptin as add\u2010on to metformin in obese type 2 diabetic patients younger than 50", "2011"], ["A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide", "2011"], ["A study of taspoglutide versus exenatide for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both", "2011"], ["A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone", "2011"], ["A study of taspoglutide versus sitagliptin for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin", "2011"], ["A study of the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin naive type 2 diabetic patients inadequately controlled with metformin plus sulphonylurea", "2011"], ["A study of taspoglutide versus placebo for the treatment of obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy", "2011"], ["A study of taspoglutide versus pioglitazone in patients with type 2 diabetes", "2011"], ["Insulinotropic hormone glucagon\u2010like peptide\u20101 differentiation of human pancreatic islet\u2010derived progenitor cells into insulin\u2010producing cells", "2002"], ["Report on the Expert Committee on the Diagnosis and Classication of Diabetes Mellitus", "1997"], ["Report of the Expert Committee on the diagnosis and classification of diabetes mellitus", "1999"], ["Efficacy and safety of incretin therapy in type 2 diabetes", "2007"], ["A recombinant human glucagon\u2010like peptide (GLP)\u20101\u2010albumin protein (albugon) mimics peptidergic activation of GLP\u20101 receptor\u2010dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis", "2004"], ["New treatments in type 2 diabetes: a focus on the incretin\u2010based therapies", "2009"], ["Glucagon\u2010like peptide\u20101 therapy and the exocrine pancreas: innocent bystander or friendly fire?", "2010"], ["A cohort study of acute pancreatitis in relation to exenatide use", "Jun 2011"], ["Assessment report for Victoza (liraglutide)", "2009"], ["Glucagon\u2010like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.[see comment]", "2003"], ["Information for Healthcare Professionals: Exenatide (marketed as Byetta)", "2008"], ["Byetta (exenatide) prescribing information", "2009"], ["Information for Healthcare Professionals: Reports of Altered Kidney Function in patients using Exenatide (Marketed as Byetta)", "2009"], ["Byetta Safety Update for Healthcare Professionals", "2009"], ["Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes", "Sep 2010"], ["Quantifying heterogeneity in a meta\u2010analysis", "2002"], ["Measuring inconsistency in meta\u2010analysis", "2003"], ["Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]", "2011"], ["FDA Reminds Clinicians of Liraglutide's Risks for Pancreatitis and Cancer", "2011"], ["Improved glycaemic control with minimal hypoglycaemiaand no weight change with the once\u2010daily humanglucagon\u2010like peptide\u20101 analogue liraglutide as add\u2010onto sulphonylurea in Japanese patients with type 2 diabetes", "2010"], ["Glucagon\u2010like peptide\u20101 receptor signaling modulates beta cell apoptosis", "2003"], ["Efficacy of exenatide therapy over 12 months in a &quot;real world&quot; setting", "2007"], ["Preferred reporting items for systematic reviews and meta\u2010analysis: the PRISMA statement", "2009"], ["Glucagon like peptide\u20101 receptor agonists in type 2 diabetes: a meta\u2010analysis of randomized clinical trials", "2009"], ["Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes", "2009"], ["Normalization of fasting hyperglycaemia by exogenous glucagon\u2010like peptide 1 (7\u201036 amide) in type 2 (non\u2010insulin\u2010dependent) diabetic patients", "1993"], ["Effects of glucagon\u2010like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers", "2002"], ["Type 2 diabetes: national clinical guideline for management in primary and secondary care", "2008"], ["Type 2 diabetes: the management of type 2 diabetes", "2009"], ["Liraglutide for the treatment of type 2 diabetes mellitus. NICE technology appraisal guidance 203", "2010"], ["Exenatide efficacy and safety: a systematic review", "2009"], ["Overview of glucagon\u2010like peptide\u20101 analogs and dipeptidyl peptidase\u20104 inhibitors for type 2 diabetes", "2008"], ["Glucagon\u2010like peptide analogues for type 2 diabetes mellitus: systematic review and meta\u2010analysis", "2010"], ["Liraglutide for the treatment of type 2 diabetes", "2011"], ["The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group", "1996"], ["UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group", "1995"], ["Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation", "July 2010"], ["Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation", "1998"], ["Exendin\u20104 stimulates both beta\u2010cell replication and neogenesis, resulting in increased beta\u2010 cell mass and improved glucose tolerance in diabetic rats", "1999"]], "ex": [["Effects of liraglutide in the treatment of obesity: a randomised, double\u2010blind, placebo\u2010controlled study", "2009"], ["Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open\u2010label, two\u2010period, crossover noninferiority trial", "2007"], ["Interim analysis of the effects of exenatide treatment on A1C,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes", "2006"], ["Patient\u2010reported outcomes following treatment with the human GLP\u20101 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes", "2010 Jul"], ["Six\u2010month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting", "2009 Dec"], ["Effects of exenatide (exendin\u20104) on glycemic control over 30 weeks in sulfonylurea\u2010treated patients with type 2 diabetes", "2004"], ["Effects of liraglutide (NN2211), a long\u2010acting GLP\u20101analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes", "2005"], ["Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time", "2010 Jan"], ["Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD\u20103 Mono): a randomised, 52\u2010week, phase III, double\u2010blind, parallel\u2010treatment trial.[see comment]", "2009"], ["Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once\u2010weekly, human GLP\u20101 analogue, after single\u2010dose administration in patients with Type 2 diabetes", "2009 Nov"], ["Effects of once\u2010weekly dosing of a long\u2010acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes", "2007"], ["Improved glycemic control with no weight increase in patients with type 2 diabetes after once\u2010daily treatment with the long\u2010acting glucagon\u2010like peptide 1 analog liraglutide (NN2211)", "2004"], ["Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo\u2010controlled, single\u2010blind, dose\u2010escalation, crossover study", "2009 Apr"], ["Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug\u2010naive patients with type 2 diabetes: a randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study", "2008"], ["The effect of liraglutide, a long\u2010acting glucagon\u2010like peptide 1 derivative, on glycemic control, body composition, and 24\u2010h energy expenditure in patients with type 2 diabetes", "2004"], ["Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes", "2010 Mar"], ["Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin", "2006"], ["Dose\u2010dependent improvement in glycemia with once\u2010daily liraglutide without hypoglycemia or weight gain: A double\u2010blind, randomized, controlled trial in Japanese patients with type 2 diabetes", "2008"], ["Clinical site experience comparing insulin glargine with exenatide treatment in type 2 diabetic patients", "2005"], ["Beneficial effects of once\u2010daily liraglutide, a human glucagon\u2010like peptide\u20101 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes", "2008"]], "in": [["Potential of albiglutide, a long\u2010acting GLP\u20101 receptor agonist, in type 2 diabetes", "2009"], ["Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION\u20102): a randomised trial", "Aug 2010"], ["DURATION\u20105: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes", "2011"], ["Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION\u20103): an open\u2010label randomised trial", "2010"], ["Improved treatment satisfaction and weight\u2010related quality of life with exenatide once weekly or twice daily", "2009"], ["Dose\u2010dependent effects of the once\u2010daily GLP\u20101 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double\u2010blind, placebo\u2010controlled trial", "2010"], ["Improved glycaemic control with minimal hypoglycaemia and no weight change with the once\u2010daily human glucagon\u2010like peptide\u20101 analogue liraglutide as add\u2010on to sulphonylurea in Japanese patients with type 2 diabetes", "2010"], ["Liraglutide, a once\u2010daily human GLP\u20101 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD\u20101 SU)", "2009"], ["Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)\u20102 study", "2009"], ["Efficacy and safety of the human glucagon\u2010like peptide\u20101 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD\u20104 Met+TZD)", "2009"], ["Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD\u20105 met+SU): a randomised controlled trial", "2009"], ["Switching from twice\u2010daily exenatide to once\u2010daily liraglutide improves glycemic control in T2D on oral agents", "2009"], ["Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26\u2010week, randomised, parallel\u2010group, open\u2010label trial", "2010"], ["The effects of LY2189265, a long\u2010acting glucagon\u2010like peptide\u20101 analog, in a randomized, placebo\u2010controlled, double\u2010blind study of overweight/obese patients with type 2 diabetes: the EGO study", "Jan 2011"], ["Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16\u2010week, randomized, double\u2010blind, active control trial", "Jan 2011"], ["Treatment with the human once\u2010weekly glucagon\u2010like peptide\u20101 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double\u2010blind placebo\u2010controlled study", "2009"], ["Safety and tolerability of high doses of taspoglutide, a once\u2010weekly human GLP\u20101 analogue, in diabetic patients treated with metformin: a randomized double\u2010blind placebo\u2010controlled study", "2010"]]}